Tectonic Therapeutic Inc (TECX)

Market Cap	259.91M
Revenue (ttm)	n/a
Net Income (ttm)	30.31M
Shares Out	14.73M
EPS (ttm)	8.28
PE Ratio	2.13
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,192
Open	17.23
Previous Close	17.00
Day's Range	17.18 - 17.85
52-Week Range	1.40 - 19.80
Beta	n/a
Analysts	Strong Buy
Price Target	76.00 (+330.84%)
Earnings Date	Aug 26, 2024

About TECX

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangie...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: TECX

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 2 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price forecast is $76.0, which is an increase of 330.84% from the latest price.

Price Target

$76.0

(330.84% upside)

Analyst Consensus: Strong Buy